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In this issue of Cancer Cell, Carretero and colleagues report that Src and FAK signaling pathways are
activated in lung cancers when the tumor suppressor LKB1 is deleted. These findings suggest the use of
unique combinatorial therapies for treatment of lung cancers.LKB1 is a serine/threonine kinase
mutated in patients with Peutz-Jeghers
syndrome. Hemizygous mutation of the
gene is associated with the formation of
hamartomas, most notably in the gastro-
intestinal (GI) tract. Individuals with this
syndrome are also predisposed to the
formation of a variety of tumors, including
those of colon, pancreas, breast, and
uterus among others (Jansen et al.,
2009). Similar to humans, mice heterozy-
gous for Lkb1 deletion are prone to the
formation of GI hamartomas and generally
die from bowel obstruction prior to true
tumor formation. Progression of the
murine hamartomas to neoplasia requires
secondary mutations, including complete
loss of LKB1 function, inactivation of
PTEN and p53 pathways, or activation of
oncogenes such as Kras. Whereas loss
of LKB1 or activation of K-Ras alone will
form non-small cell lung cancer (NSCLC)
in mouse model systems, the combina-
tion of both mutations produces more
aggressive, metastatic tumors. Further-
more, patients with NSCLC having both
activating K-RasG12V and loss of LKB1
function mutations suffer a poorer prog-
nosis than do individuals with NSCLC
having K-RasG12V alone. The mechanism
by which LKB1 deficiency enhances
tumor progression remained largely
unknown.
Carretero et al. (2010) now reveal a
possiblemeans bywhich LKB1 influences
NSCLC tumorigenesis and metastasis.
Making use of the KrasG12V/Lkb1/
mouse model for NSCLC, the authors
compared gene expression and phos-
phoproteome profiles between primary
KrasG12V tumors and primary KrasG12V/
Lkb1/ tumors as well as metastatic
KrasG12V/Lkb1/ tumors and either of
the primary tumors. Loss of LKB1 in theprimary tumor resulted in increased
expression of genes associated with the
FAK/Src and PI3K/AKT pathways. In
addition to these pathways, metastatic
tumors showed increases in epithelial-
mesenchymal transition (EMT), stem cell,
and growth factor pathways. Src has
been demonstrated to affect many of the
processes regulated by these pathways,
including mitogenesis, cell survival,
migration/metastasis, and angiogenesis/
hypoxia (Ishizawar and Parsons, 2004).
Indeed, Carretero et al. (2010) showed
increased Src activity and FAK expres-
sion in NSCLC cells lacking LKB1, which
correlated with increased migration and
invasion. Importantly, targeting the PI3K/
AKT, MAPK, and Src pathways in the
KrasG12V/Lkb1/ mice significantly re-
duced tumor burden compared to target-
ing either Src alone or PI3K/AKT and
MAPK, thus demonstrating the impor-
tance of these pathways in tumor pro-
gression.LKB1 and Src in Tumorigenesis
LKB1 negatively regulates cell growth,
angiogenesis, and bioenergetics through
the Ser/Thr kinase AMP kinase (AMPK)
under conditions of nutrient or oxygen
stress, conditions often present in tumors.
Upon LKB1-mediated phosphorylation,
AMPK becomes activated, inducing
p53-mediated cell cycle arrest, downre-
gulating expression of genes involved in
gluconeogenesis and lipogenesis, upre-
gulating genes involved in catabolism,
and inhibiting mTOR-mediated protein
synthesis. These actions result in reduced
cell cycle progression, cell growth, glycol-
ysis, and angiogenesis, all features of
a bona fide tumor suppressor. It is postu-
lated that depletion of LKB1 relieves theseCancer Cellconstraints, which in the appropriate cell
context results in tumorigenesis.
As Carretero and colleagues demon-
strate, loss of LKB1 expression does
more than relieve constraints on cell
growth. The increased activity of Src and
downstream signaling components as a
result of LKB1 depletion provides evidence
to support the active stimulation of growth
regulatory pathways. One example is illus-
trated by the effects of LKB1 and Src on
mTor-mediated protein synthesis. Src
positively regulates mTOR through PI3K/
Akt, whereas AMPK negatively regulates
mTOR through Raptor and TSC2 (Shaw,
2009). The observation that LKB1 loss
leads to increasedSrcactivity andelevated
expression of PI3K/Akt pathway compo-
nents indicates that LKB1 deficiency not
only relieves the negative regulation of
mTOR but also promotes its activity.
Another potential node of integration for
LKB1 and Src signaling is the regulation of
the cell’s energy metabolism. In addition
to negatively regulating cell cycle pro-
gression, cell growth, and glycolosis,
AMPK stimulates expression of genes
involved in mitochondrial biogenesis to
enhance ATP production. This is accom-
plished in part through phosphorylation
and activation of the transcription factor,
PPARg coactivator 1a. Src, too, has
been localized to the mitochondria, where
evidence suggests that it regulates EGF/
EGFR-mediated reduction in ATP through
phosphorylation of cytochrome c oxidase
II (Demory et al., 2009). Together, the loss
of AMPK activity coupled with increased
Src activity as a result of LKB1 depletion
is expected to decrease ATP production
by the electron transport system. This
hypothesis is consistent with the shift
to anaerobic glycolysis characteristic of
highly proliferative cells.17, June 15, 2010 ª2010 Elsevier Inc. 527
Figure 1. Antagonistic Action of LKB1 and Src Pathways Regulates Cell Growth and
Migration
LKB1-induced activation of AMPK negatively modulates mTOR, whereas Src/PI3K signaling enhances
mTOR function. In addition to mTOR regulation, Src and LKB1 may also regulate cell growth through
the modulation of ATP production. Src and FAK promote cellular migration, in part through activation of
PAK1. Conversely, LKB1 negatively regulates PAK1 activity by direct phosphorylation, reducing migra-
tion. Currently the mechanism by which LKB1 loss upregulates Src expression and activity, or whether
the interaction between these pathways is unidirectional, remains unclear.
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A prerequisite of metastasis is increased
migration. This is thought to occur as cells
undergo EMT, a process that involves
transcriptional upregulation of vimentin,
fibronectin, TGF-b, Snail, and Twist, as
well as diminished expression of E-cad-
herin. The EMT signature observed by
Carretero et al. (2010) in metastatic
KrasG12V/Lkb1/ tumors is difficult to
ascribe purely to the loss of LKB1,
because it is not observed in the primary
LKB1-deficient tumors, but rather may
represent a hallmark of metastasis.
However, the loss of LKB1 did modulate
pathways that regulate migration. Gene
expression profiling demonstrated that
Src, FAK, and p130Cas were elevated in
KrasG12V/Lkb1/ tumors compared to
KrasG12V tumors, and phosphotyrosine
profiling identified FAKandpaxillin, critical
regulators of cellular migration.528 Cancer Cell 17, June 15, 2010 ª2010 ElsThe LKB1 and FAK/Src pathways also
regulate the migratory process through
their action on p21-activated kinase
(PAK1). PAK1 functions downstreamof the
small GTPases Rac and Cdc42 to regulate
adhesion turnover and actin dynamics, in
part by phosphorylating paxillin (Nayal
et al., 2006). FAK/Src signaling promotes
PAK1 activation leading to increased
migration (Slack-Davis andParsons, 2004).
Conversely, LKB1 negatively regulates
PAK1 activity by direct phosphorylation of
Thr109, reducing migration (Deguchi
et al., 2010). Thus, with regard to PAK1
activity and cell migration, the activities of
LKB1 andSrc are antagonistic. It shouldbe
noted that LKB1 has been shown to posi-
tively regulate polarity of migrating cells
by recruiting active Cdc42 to the leading
edge tostimulatePAK1;however, theover-
all impact of this process on cell migration
was not examined (Zhang et al., 2008).evier Inc.Implications for Lung Cancer
Therapy
The finding that Src/FAK pathways are
involved in the progression of LKB1-defi-
cient tumors, most notably lung, where
therapeutic options are minimal, reveals
new combinatorial treatment possibilities.
The recent successeswith small molecule
and antibody inhibitors of the EGFR in
subsets of NSCLC patients, as well as
the development and encouraging initial
testing of competitive ATP analogs for
inhibition of Src and FAK, suggest that
combinations of these agents might be
beneficial for a larger pool of NSCLC
patients, regardless of their LKB1 status.
To this end, a combination of Src and
EGFR inhibitors has been used in a Phase
I study of advanced/metastatic NSCLC
(Haura et al., 2010). Results indicate that
the combination was tolerated and 62%
experienced responses. However, for
patientswho exhibit LKB1 heterozygosity,
combination of activators of AMPK and
one or more tyrosine kinase inhibitors
might bemore efficacious (e.g.,metformin
with dasatinib). These strategies, molded
to individual molecular signatures, hold
much promise for patients with tumors
harboring mutations in the LKB1 gene.Conclusion
Taken together, this work unambiguously
linksSrc/FAKsignalingwith LKB1 function
and identifies novel cooperatingpathways
that promote the progression of lung
cancers to a metastatic state (Figure 1).
Further characterization of the interaction
between these pathways will be of great
interest. Understanding whether the loss
of LKB1 function is context dependent or
will generate similar signatures of pathway
modulation when oncogenic progression
is driven in conjunction with PTEN, p53,
or B-Raf mutation instead of K-RasG12V
will enhance rational approaches for ther-
apeutic intervention.REFERENCES
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The role of GSK-3 in oncogenesis is paradoxical, acting as a tumor suppressor in some cancers and poten-
tiating growth in others. In this issue ofCancer Cell, Wang et al. provide somemechanistic insight into GSK-3
activity’s role in potentiating leukemias which are dependent on homeobox (HOX) gene misregulation.Glycogen synthase kinase-3 (GSK-3) was
first identified for its role in regulating
glycogen metabolism but has since been
shown to be involved in the regulation
of a variety of processes including signal
transduction, gene expression, and cell-
fate determination (Jope and Johnson,
2004). These critical roles have become
increasingly more appreciated as misre-
gulated GSK-3 has been implicated in
neurological disorders (i.e., Alzheimer’s
disease and bipolar disorder), non-
insulin-dependent diabetes mellitus,
stroke, and neoplasias (Cohen andFrame,
2001; Rayasam et al., 2009). With over
40 proteins identified as potential GSK-3
substrates, it is not surprising that a
complicated network of GSK-3 func-
tioning has emerged (Jope and Johnson,
2004). This complexity is particularly
evident in cancer where GSK-3 can take
on seemingly opposing roles in tumor
suppression or promotion (Ougolkov and
Billadeau, 2006; Luo, 2009).
Decreased expression or activity of
GSK-3 has been associated with skin
and breast tumors. In vitro and in vivo
rescue experiments in which active
GSK-3 is restored to transformed tumor-
cells leads to suppression of cell prolifer-
ation. Tumor-suppressive functioning ofGSK-3 has been shown to involve the
WNT signaling pathway in which active
GSK-3 negatively regulates b-catenin
through inhibitory phosphorylation and
prevents transcription of b-catenin target
genes involved in cell-cycle progression
(Figure 1). Decreased expression or
activity of GSK-3 could, then, activate
theWNT signaling pathway through stabi-
lization of b-catenin and contribute to
tumorigenesis (Luo, 2009; Rayasam
et al., 2009). In contrast, overexpression
of active GSK-3 is associated with
increased proliferation and decreased
patient survival of some cancers through
pathways which are thought to involve cy-
clin D1 and NF-kB (Luo, 2009).
This opposing function of GSK-3 as
a tumor promoter has also been sug-
gested for acute leukemia in a report by
Wang and colleagues in which MLL-asso-
ciated leukemia was shown to depend on
GSK-3 for sustained proliferation of trans-
formed cells (Wang et al., 2008). Pharma-
cologic inhibition of GSK-3 caused
decreased proliferation, reduced cell-
cycle progression, and increased myeloid
differentiation of leukemia cells that had
been transformed with chimeric MLL on-
coproteins. Decreased GSK-3 activity in
MLL leukemia cells was associated withincreased levels of b-catenin, decreased
cell proliferation in vitro, and enhanced
survival of mice with these leukemias
in vivo. An increase in the CDK inhibitor,
p27Kip1, expression was observed specif-
ically in MLL leukemia cells upon treat-
ment with GSK-3 inhibitors suggesting
that GSK-3 may override cell-cycle regu-
lators in MLL cells to enhance prolifera-
tion, though the exact mechanism re-
mained unclear.
In the current issue of Cancer Cell,
Wang et al. present a follow-up of their
previous study where they begin to delin-
eate the mechanism whereby MLL leuke-
mias depend on GSK-3 for maintenance
of proliferation and transformation (Wang
et al., 2010). Their data demonstrate that
GSK-3 activity promotes the formation
of a HOX/MEIS1/CREB complex that
recruits coactivators CBP and TORC to
maintain the MLL leukemia stem cell tran-
scription program. It has been well estab-
lished that homeobox (HOX) genes
become misregulated in aggressive
leukemias involving MLL translocations
(Shah and Sukumar, 2010). During normal
hematopoiesis, MLL maintains appro-
priate HOX gene expression in hemato-
poietic stem and progenitor cells. As
progenitor cells mature into differentiated17, June 15, 2010 ª2010 Elsevier Inc. 529
